Helicobacter Infections
30
1
2
21
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
3.3%
1 terminated out of 30 trials
95.5%
+8.9% vs benchmark
37%
11 trials in Phase 3/4
10%
2 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (30)
Helicobacter Pylori Infection and Gastric Diseases in Lao PDR: First Community-Wide Population-Based Study
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
Helicobacter Pylori Eradication to Prevent Gastric Cancer
Specimen Collection Study for H. Pylori Testing
Association Between Helicobacter Pylori and Inflammatory Bowel Disease
Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
A Unique Regimen for Treatment of Helicobacter Pylori Infection
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
Helicobacter Pylori and Proton Pump Inhibitor
Inflammation, Infection, and Future Cardiovascular Risk
Infection and Cardiovascular Disease
Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection
Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy
A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection
Eradication Rates of Helicobacter Pylori and Its Affecting Factors
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy